Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Impax, J&J clash over Concerta ANDA, Watson gains certainty with its J&J deal

This article was originally published in Scrip

Executive Summary

Johnson & Johnson's Alza unit has sued Impax Laboratories in federal court, seeking to halt Impax from marketing a generic version of the attention-deficit hyperactivity disorder treatment Concerta (methylphenidate HCl extended release) before a US patent expires in 2018 and connected to the extended-release 54mg tablets. Meanwhile, the market has adjusted to Watson's 2 November announced deal on generic Concerta with J&J, under which Watson will launch a J&J-supplied authorised generic in 2011, with rights to continue selling the authorised generic through 2014.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC010961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel